z-logo
Premium
Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide
Author(s) -
Umpierrez Guillermo,
Pantalone Kevin M.,
Atisso Charles M.,
Landó Laura Fernández,
Patel Hiren
Publication year - 2019
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13662
Subject(s) - dulaglutide , postprandial , medicine , exenatide , basal (medicine) , type 2 diabetes , insulin glargine , basal insulin , area under the curve , liraglutide , diabetes mellitus , endocrinology , insulin
Aim To assess the effect of dulaglutide on the relative contribution of basal hyperglycaemia (BHG) and postprandial hyperglycaemia (PPHG) to overall hyperglycaemia across HbA1c categories in patients with type 2 diabetes. Methods Data from five phase 3 studies (N = 673) were pooled to assess the change in relative contributions of BHG and PPHG to overall hyperglycaemia across different HbA1c categories after 6 months of treatment intensification with dulaglutide 1.5 mg as monotherapy or with 1 or 2 oral medication(s) in patients with type 2 diabetes. BHG and PPHG were calculated using the area under the curve (AUC) of 7‐point self‐monitored plasma glucose concentration profiles. As a secondary objective, relative contribution of BHG and PPHG for dulaglutide versus liraglutide, exenatide BID and insulin glargine was assessed by individual studies at 6 months. Results In pooled data, after 6 months of treatment intensification with dulaglutide 1.5 mg, there was a significant reduction from baseline in overall hyperglycaemia (AUC overall ) [(mean ± SE) ‐466.31 ± 18.32 mg*h/dL ( P < 0.001)], BHG (AUC basal ) [(mean ± SE) ‐371.46 ± 16.36 mg*h/dL ( P < 0.001)] and PPHG (AUC postprandial ) [(mean ± SE) ‐94.84 ± 7.97 mg*h/dL ( P < 0.001)]. At baseline, relative contributions of BHG increased and PPHG decreased with increasing HbA1c levels. This pattern was maintained at 6 months, even as overall glycaemia improved with decreasing HbA1c values. Conclusions In patients with type 2 diabetes, dulaglutide reduces HbA1c by lowering both basal and postprandial hyperglycaemia across various HbA1c levels.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here